Ivonescimab for previously treated metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced colorectal cancer that has spread to other parts of the body
- Your doctor knows your tumor's MSI or MMR status (a special marker that helps predict response to immunotherapy)
- You have already tried and failed standard chemotherapy (fluoropyrimidine, irinotecan, oxaliplatin) or you could not tolerate them
- You are in fairly good health (ECOG score 0-1) and have adequate organ function
- You can provide a recent tumor tissue sample (biopsy or archived)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This study tests a new immunotherapy medicine, ivonescimab, in people with advanced skin cancer or advanced prostate cancer. It looks at how safe and effective the drug is.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.